GO
GO
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
1
$263K
Insider Sales
0
$0
Total Volume
$263K
1 transactions
Net Activity
+$263K
Net buying
Sentiment Rating
Moderate AccumulationCEO Conviction Index
No Recent Signal
Key Drivers
- •Strong buying bias: purchases represent 100% of total transaction value.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
GO has an insider buy conviction of 100%, compared to the Unknown sector buy average of 50%.
Multiple Insiders
2 Insiders
$263K total
Over the last 90 days, corporate insiders at GO (GO) engaged in a total of 1 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 0 were sales. The total volume of insider trading reached $263K.
The net insider activity for GO shows a net buying bias of $263K. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Purchase by Multiple Insiders (2 Insiders), who traded 23.0K shares valued at $263K on Aug 20, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering GO and the Unknown sector.
The Quant Guide: Backtesting SEC Form 4 Cluster Buys for Alpha
A rigorous quantitative backtest of SEC Form 4 cluster buying activity, demonstrating how to isolate signal from noise and build portfolios that consistently outperform benchmarks.
Tracking Insider Activity in Biotech: High Stakes and Hidden Signals
Biotech insiders possess unique asymmetric information, clinical results, FDA feedback, partnership negotiations. This guide explains how to track Form 4 activity at pre-commercial biotechs, what position sizes matter, and how to avoid false signals near data events.
The Role of Independent Directors in Monitoring C-Suite Transactions
Independent directors are the gatekeepers of executive trading compliance, but their oversight varies widely. This report grades governance quality at Fortune 500 companies by examining how strictly independent directors enforce pre-clearance policies.
Short-Swing Profit Rules: Why Insiders Cannot Trade in Under Six Months
Section 16(b) forces insiders to disgorge any profits from buy-then-sell or sell-then-buy transactions completed within six months. This guide explains the rule mechanics, common loopholes, and why it creates predictable Form 4 patterns.
The Danger of Following 'Dump' Filings: Sells That Mean Nothing
Form 4 sell transactions flood the tape daily, RSU vesting, option exercises, 10b5-1 plan executions. This guide documents the seven categories of insider sales that carry zero predictive value and how to filter them from your screener.
Institutional Ownership vs. Insider Holdings: Who Has More Influence?
When BlackRock and Vanguard own 15% of a company and the CEO owns 0.5%, whose incentives drive capital allocation decisions? This report compares activist institutional pressure against insider ownership depth as governance indicators.
FAQs About GO Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for GO.